MeiraGTx, a New York-based genetic medicine company, has partnered with London-based AI drug development firm Hologen AI to form a joint venture called Hologen Neuro AI Ltd. As part of the deal, MeiraGTx will receive $200 million in upfront cash, with Hologen committing up to $230 million in additional funding. This capital will support the development of AAV-GAD for treating Parkinson’s disease and early-stage CNS programmes like AAV-BDNF for genetic obesity. The venture will leverage Hologen’s proprietary multi-modal generative AI models to revolutionise how therapies for neurodegenerative and neuropsychiatric disorders are discovered and developed.

MeiraGTx will retain a 30% stake in Hologen Neuro AI and will lead clinical development and manufacturing, entering exclusive supply agreements under the project. Hologen will take a minority stake in MeiraGTx’s manufacturing subsidiary, enhancing operations through its AI capabilities. By combining Hologen’s generative AI with MeiraGTx’s proprietary manufacturing data, developed over nine years, the collaboration aims to optimise manufacturing and establish the first neuro-AI clinical drug development company.